TCT-34 Reduction of Infarct Size in Anterior ST-Segment Elevation Myocardial Infarction (STEMI) With LAD Occlusion and LV Unloading Using a Micro-axial Pump for 30 Minutes Before PCI: Per-Protocol Analysis of the STEMI Door to Unload (DTU) Pilot Study

Background: The STEMI-DTU pilot trial identified that LV unloading before PCI is safe and feasible in anterior STEMI without shock. We now report findings from patients who met all protocol inclusion and exclusion criteria. Methods: In a multicenter, randomized safety and feasibility trial, 50 patients with anterior STEMI were unloaded using the Impella CP followed by immediate (U-IR) or delayed PCI after 30 minutes of unloading (U-DR). Cardiac magnetic resonance (CMR) imaging assessed infarct size 3-5 days after PCI. Patients without CMR at 3-5 days (n = 10; 5/arm), without PCI of a culprit LAD lesion (n = 2; 1/arm) and without STEMI (n = 5; 4 U-IR, 1 U-DR) were not per protocol and thus excluded. Results: 33 patients met all inclusion and exclusion criteria (U-IR n = 15, U-DR n = 18) with respective door-to-balloon times of 75 ± 26 and 89 ± 23 minutes (P = 0.10) and mean unload-to-balloon times of 10 ± 5 and 34 ± 3 (P \u3c 0.01). In the total cohort 2-5 day IS was significantly associated with microvascular obstruction (MVO), 30-day IS normalized to total LV mass, 90 day LVEF, and 90 day LV end systolic volume with or without delayed reperfusion (Table) (R \u3e 0.5, P \u3c 0.005 for all). Despite longer symptom to balloon times in the U-DR arm (174 ± 59 vs 228 ± 78, P \u3c 0.01) IS/AAR was lower in the U-DR arm (62 ± 16 vs 48 ± 16, P = 0.04) and remained lower irrespective of STE magnitude. MVO was lower in the U-DR arm among patients with the highest STE (Figure). Conclusion: A per-protocol analysis of the STEMI-DTU Pilot trial identified reduced infarct size with unloading and delayed reperfusion. These findings are under investigation in the STEMI-DTU Pivotal trial. Categories: CORONARY: Acute Myocardial Infarctio

Gender disparities with the use of percutaneous left ventricular assist device in patients undergoing percutaneous coronary intervention complicated by cardiogenic shock: From pVAD Working Group

Background: Hemodynamic support with Impella (Abiomed Inc., Danvers, MA) devices is becoming a more prevalent treatment option for patients with cardiogenic shock (CS) undergoing percutaneous coronary intervention (PCI). There exists only limited published data regarding outcome differences between male and female patients. Therefore, the objective of this paper is to analyze these gender differences between short-term survival and in-hospital outcomes in those undergoing PCI with CS. Methods: Between January 2011 and July 2016, patients undergoing PCI with simultaneous use of Impella were identified. Only patients presenting with CS were included in the analysis. All-cause in-hospital mortality was the primary outcome. Using SAS 9.4 for propensity score matching, additional secondary outcomes were also compared. Results: The primary outcome was comparable between males and females (39.5% vs. 26.3%, p = 0.33) in CS patients. Secondary outcomes were also comparable and included: myocardial infarction, stroke, CS, heart failure, dialysis requirement, bleeding within 72 h, blood transfusion, dysrhythmia, composite of all complications, major adverse cardiac events. Survival at 30 days was equal in both groups. A reduced mortality in males was noted for pre-PCI initiation of Impella. Additionally, both genders who received pre-PCI Impella support, experienced a significant reduction in inotrope use. Conclusions: Despite the small number of cohorts, this study did not reveal any significant differences among gender with the use of percutaneous left ventricular assist devices for PCI in patients with acute myocardial infarction complicated by CS. However, initiation of Impella prior to PCI may be associated with improved mortality and morbidity in both genders. Keywords: Mechanical circulatory device, Cardiogenic shock, High-risk PCI, Gende

Impella 25 initiated prior to unprotected left main PCI in acute myocardial infarction complicated by cardiogenic shock improves early survival

OBJECTIVES: To assess post-procedural outcomes when Impella 2.5 percutaneous left ventricular assist device (pLVAD) support is initiated either prior to or after percutaneous coronary intervention (PCI) on unprotected left main coronary artery (ULMCA) culprit lesion in the context of acute myocardial infarction cardiogenic shock (AMICS). BACKGROUND: Initiation of Impella 2.5 pLVAD prior to PCI is associated with significant survival benefit in the setting of AMICS. Outcomes of those presenting with a ULMCA culprit lesion in this setting have not been well characterized. METHODS: Thirty-six consecutive patients in the cVAD Registry supported with Impella 2.5 pLVAD for AMICS who underwent PCI on ULMCA culprit lesion were included in our multicenter study. RESULTS: The average age was 69.8 ± 14.2 years, 77.8% were male, 72.7% were in CS at admission, 44.4% sustained one or multiple cardiac arrests, and 30.6% had anoxic brain injury. Baseline characteristics were comparable between the Pre-PCI group (n = 20) and Post-PCI group (n = 16). Non-ST segment elevation myocardial infarction and greater coronary disease burden were significantly more frequent in the Pre-PCI group but they had significantly better survival to discharge (55.0% vs 18.8%, P = 0.041). Kaplan-Meier 30-day survival analysis showed very poor survival in Post-PCI group (48.1% vs 12.5%, Log-Rank P = 0.004). CONCLUSIONS: Initiation of Impella 2.5 pLVAD prior to as compared with after PCI of ULMCA for AMICS culprit lesion is associated with significant early survival. As previously described, patients supported after PCI appear to have very poor survival at 30 days